RACHEL RHINEHART: Open Payments
NPI 1780212605 · JEFFERSON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$13,499 in 66 payments from 12 companies in 2025. Trend: 2023 $781 · 2024 $1,259 · 2025 $13,499
Honoraria: $8,160Travel & lodging: $2,336Food & beverage: $1,856Education: $1,148
| Company | Payments | Amount |
|---|---|---|
| Amneal Pharmaceuticals LLC | 17 | $11,893 |
| ABBVIE INC. | 23 | $451 |
| Teva Pharmaceuticals USA, Inc. | 6 | $317 |
| MDD US Operations, LLC | 5 | $192 |
| ACADIA Pharmaceuticals Inc | 4 | $182 |
| Ipsen Biopharmaceuticals, Inc | 2 | $154 |
| Neurocrine BioSciences, Inc. | 1 | $120 |
| Biogen, Inc. | 2 | $49 |
| Merz Pharmaceuticals, LLC | 2 | $44 |
| Eisai Inc. | 2 | $38 |
Products named: CREXONT, AUSTEDO XR, VYALEV, NUPLAZID, Dysport, INGREZZA, BOTOX, QULIPTA.
Industry payments across LA — which companies pay providers there.
